Engelsk titel: Adalimumab in the treatment of rheumatoid arthritis
Läs online
Författare:
Bendtzen K
Email: kben@mail.dk
Språk: Dan
Antal referenser: 10
Dokumenttyp:
Artikel
UI-nummer: 04061442
Sammanfattning
Adalimumab is a genetically engineered human monoclonal IgG1:a antibody to human TNF-a . It inhibits TNF-a -induced functions and may lyse cells with TNF-a expressed on the surface. Studies have shown beneficial effects on clinical, biochemical and radiographic parameters in at least 50% of adult patients with rheumatoid arthritis. Treatment is generally well tolerated, but local reactions at the injection sites and infections, including serious infections, have been reported. Induction of neutralising antibodies may be a problem despite the "human" nature of the drug.